In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 281 to 290 of 303

TitleTypeExpected publication date
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]Technology appraisal guidanceTBC
Tusamitamab ravtansine for previously treated CEACAM5-positive metastatic non-squamous non-small-cell lung cancer [ID4061]Technology appraisal guidanceTBC
Ublituximab for treating relapsing multiple sclerosis [ID6350]Technology appraisal guidanceTBC
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]Technology appraisal guidanceTBC
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Technology appraisal guidance
Vamorolone for treating Duchenne muscular dystrophy [ID4024]Technology appraisal guidanceTBC
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people 6 years and over ID6372Technology appraisal guidanceTBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]Technology appraisal guidanceTBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]Technology appraisal guidanceTBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All